CD93 and melanoma: Additionally, blockade of CD93 resulted in improved perfusion of subcutaneously implanted pancreatic and melanoma tumors, suggested by decrease in intratumoral hypoxia with improved tomato lectin staining of intratumoral vessels and hypoxic inducible factor 1 alpha (HIF1α) expression—this is in direct opposition to results reported in CD93 KO gliomas where CD93 knockdown mice exhibited worse perfusion than WT counterparts [41].